Aluminum toxicity in neonatal parenteral nutrition: what can we do?

Area of Science:

• Neonatology
• Clinical Pharmacy
• Toxicology

Background:

• Aluminum toxicity is a concern in patients receiving dialysis, phosphate binders, and parenteral nutrition (PN).
• Neonates possess distinct anatomic, physiologic, and nutritional characteristics that elevate their risk of aluminum toxicity compared to other age groups.

Purpose of the Study:

• To highlight the increased risk of aluminum toxicity in neonates.
• To discuss the challenges in managing aluminum exposure in neonatal intensive care.

Main Methods:

• Review of existing literature on aluminum toxicity in various patient populations.
• Analysis of Food and Drug Administration (FDA) recommendations regarding aluminum content in PN.
• Discussion of the role of pharmacists in mitigating aluminum exposure.

Main Results:

• Neonates are particularly vulnerable to aluminum toxicity due to specific developmental factors.
• Current FDA regulations mandate limits on daily aluminum administration (5 μg/kg/day) and require labeling of aluminum content in PN additives.
• Despite these measures, achieving the recommended low aluminum threshold in neonatal PN is difficult.

Conclusions:

• Aluminum toxicity poses a significant risk to neonates undergoing medical therapies.
• Pharmacists play a crucial role in minimizing aluminum exposure, but clinical challenges persist in meeting safety targets for this vulnerable population.